🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's recent agreements with Washington are "fundamentally unstable." This stems from revelations that a recently announced deal on drug pricing, which commits to zero tariffs in exchange for the NHS paying more, lacks any formal legal text beyond broad headline terms outlined by government press releases.

A Deal Without Detail

The deal on drug tariffs, hailed as a "generational" achievement, exists as an "statement of intent" without detailed provisions. It has been highlighted that the official announcements from the UK and US governments describe the deal in divergent terms. The British version celebrates securing "duty-free access" as a unique achievement, while the American announcement concentrates on the commitment for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to raise drug prices in return for nothing more than a pledge from President Trump," said David Henig, a trade policy analyst. "It is documented he has a record of not honouring his word."

Wider Concerns Amidst a Suspended Agreement

Anxieties have been intensified by Washington's recent decision to pause the major technology agreement, which was previously heralded as "a generational step-change" in the bilateral relationship. The US cited a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions agreed to for British farmers as part of an earlier tariff deal have not been formally ratified by the US, despite a imminent January deadline. "It is our belief that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have expressed concerns that the government's agreements with the US are flimsy and unreliable. One minister described the series of agreements as "built on sand," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, argued: "The only thing more surprising than Trump's temper tantrums is the UK government's credulous faith that his administration is a good faith actor. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have sought to reduce the risk of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that volatility is part and parcel of dealing with the current US leadership. However, they maintain that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is better than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, delays have emerged in carrying out the broader trade deal. Promised reciprocal agricultural allowances have failed to be approved, and the commitment to "remove tariffs on British steel and aluminium" has not been fulfilled, with tariffs fixed at 25%.

Looking ahead, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.